Data for: Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy

Published: 14 February 2019| Version 1 | DOI: 10.17632/by62p9c6hg.1
Contributor:
Huijuan Wang

Description

Supplement 1. Major clinicopathological characteristics of 4276 cases.

Files

Categories

National Institute of Clinical Excellence

Licence